Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human papillomavirus nonavalent vaccine
- Development stage
- Phase 3
- Lead developer
- Shanghai Bovax Biotechnology
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Recombinant human papillomavirus nonavalent vaccine is a multivalent vaccine designed to protect against nine types of human papillomavirus (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58). This specific candidate, developed by Shanghai Bowei Biotechnology (a subsidiary of Mabwell), utilizes a *Hansenula polymorpha* (yeast) expression system to produce recombinant virus-like particles (VLPs) of the L1 major capsid protein. These VLPs self-assemble to mimic the structure of the native virus, eliciting a potent neutralizing antibody response without being infectious. The vaccine is intended for the prevention of cervical, vaginal, and vulvar cancers, as well as genital warts and other HPV-related malignancies. It is currently in Phase III clinical trials in China, where its immunogenicity and safety are being evaluated in comparison to the reference product, Gardasil 9.
- Brand names
- Cecolin 9Cecolin9Cecolin-9
- Other names
- recombinant human papillomavirus nonavalent vaccine (Hansenula polymorpha)9-valent HPV vaccinerecombinant HPV nonavalent vaccine
02
Targets
HPV L1 (Human papillomavirus L1 capsid protein)HSPG (Basement membrane-specific heparan sulfate proteoglycan core protein (perlecan))BCR (Immunoglobulin G B Cell Receptor)HPV11 L1HPV16 (Human papillomavirus type 16)HPV18 L1HPV31 L1HPV33 L1HPV45 L1HPV52 L1 (Human papillomavirus type 52 major capsid protein L1)HPV58 L1 (Human papillomavirus type 58 major capsid protein L1)HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)
Beyond the preview
Go deeper on recombinant human papillomavirus nonavalent vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human papillomavirus nonavalent vaccine.